Searchable abstracts of presentations at key conferences in endocrinology

ea0034p89 | Clinical practice/governance and case reports | SFEBES2014

Low dose tolvpatan (7.5 mg) is effective in the management of SIADH in oncology patients (results from a retrospective audit at The Christie Hospital and Wythenshawe Pulmonary Oncology Unit)

King Jennifer , Kyriacou Angelos , Issa Basil , Taylor Paul , Higham Claire

Tolvaptan (a selective V2 receptor antagonist) is licensed for the inpatient management of SIADH induced hyponatraemia, a common complication in patients with malignancy. Licensed daily doses start at 15 mg but there is evidence that some patients have a rise in serum sodium (Na) of >12 mmol/l per 24 h in response to this. Lower initial doses (7.5 mg) may therefore be appropriate1,2.Methods: A retrospective case note audit was performed. T...

ea0086p52 | Metabolism, Obesity and Diabetes | SFEBES2022

Nrf2 activator Sulforaphane attenuates maternal adiposity and hepatic steatosis

Psefteli Paraskevi-Maria , Balagamage Alokya , Morris Jessica , Taylor Paul , Mann Giovanni , Chapple Sarah

Intro/Aims: Maternal obesity is a major risk factor for the development of first onset of diabetes in pregnancy, also known as gestational diabetes mellitus (GDM). Recent studies also indicate that non-alcoholic fatty liver disease (NAFLD) is an independent predictor of GDM. Sulforaphane (SFN) is a well-known dietary activator of the redox-sensitive transcription factor Nrf2, with reported anti-adipogenic and NAFLD ameliorating effects in non-pregnant obese rodent models. In t...

ea0086p55 | Metabolism, Obesity and Diabetes | SFEBES2022

Effect of sulforaphane, an activator of the Nrf2 antioxidant defence pathway, on maternal adiposity in a model of diet-induced insulin resistant pregnancy

Balagamage Alokya , Psefteli Paraskevi-Maria , Morris Jessica , Taylor Paul , Mann Giovanni , Chapple Sarah

The incidence of maternal obese and/or gestational diabetic (GDM) pregnancy are increasing globally, with ~10-20% of mothers classified as obese and/or GDM within the U.K. Both obese and GDM pregnancy are associated with increased risk of cardiometabolic disease, with mothers and their children at greater risk of developing later-life Type 2 diabetes, obesity and/or cardiovascular disease. Higher adiposity in pregnancy leads to increased inflammation, which may be countered by...

ea0086p203 | Metabolism, Obesity and Diabetes | SFEBES2022

Monitoring obesity-induced hyperglycaemia and insulin sensitivity in obese murine pregnancy

Morris Jessica , Kennard Matilda , Farrel-Dillon Keith , Taylor Paul , Bowe James , Gnudi Luigi , Nandi Manasi , Chapple Sarah

During pregnancy progressive maternal insulin resistance occurs which is normal, ‘sparing’ glucose that can be transported across the placenta to be used by the fetus. In gestational diabetes mellitus (GDM) maternal glucose dysregulation is exacerbated, characterised by hyperglycaemia and associated with long-term adverse outcomes in mother and child, such as increased risk of diabetes and/or cardiovascular disease in later-life. Continuous glucose monitoring (CGM) i...

ea0034p205 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2014

Cross-sectional survey of depression and anxiety in a clinical diabetes population: prevalence and role in blood sugar control

Lakhani Hammad , Cane Isobel , Taylor Michelle , Chadwick Paul , Rosenthal Miranda

Aims: To evaluate the prevalence of depression and anxiety in adult outpatients with diabetes and identify the correlation with diabetes management behaviours and clinical outcomes.Methods: Cross-sectional analyses were performed on 142 diabetic patients (type 1 diabetes n=67, type 2 diabetes n=60) attending outpatient clinic. Depression and anxiety were evaluated using the Patient Health Questionnaire (PHQ-2) and the General Anxiety Di...

ea0065p138 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Targeting oestrogen synthesis and action as a novel therapy for colorectal cancer

Sidhu Daljit , Haime Hope , Pidd Aidan , Taylor Angela , Cox Liam , Foster Paul

Colorectal cancers (CRC) represent 9.4% of all cancers, with about 42 000 new UK cases per year. Current treatment involves surgical resection followed by radio- and chemo-therapy. 5-Fluorouracil is the standard post-operative chemotherapy although tolerance is poor due to dose-limiting toxicities and drug-resistance. New treatment strategies are therefore sorely needed. One emerging chemotherapeutic option is to target oestrogen metabolism. Our novel work rev...

ea0041oc9.3 | Endocrine Tumours | ECE2016

Stressed to death – antioxidant pathway targeting as a novel therapeutic approach in adrenocortical carcinoma

Chortis Vasileios , Taylor Angela E , Doig Craig L , Meimaridou Eirini , Metherell Louise A , Arlt Wiebke , Foster Paul A

Context: Nicotinamide nucleotide transhydrogenase (NNT) is a NADPH-generating mitochondrial proton pump with a central role in mitochondrial antioxidant pathways. Recent studies revealed inactivating NNT mutations in patients with familial glucocorticoid deficiency, indicating a selective susceptibility of the adrenal cortex to NNT deficiency and oxidative stress. Here we explored the potential value of NNT as a therapeutic target in adrenocortical cancer.<p class="abstext...

ea0038p145 | Neoplasia, cancer and late effects | SFEBES2015

Nicotinamide nucleotide transhydrogenase (NNT) as a novel molecular target in adrenocortical carcinoma – impact of NNT knockdown on adrenocortical cell proliferation, redox balance and steroidogenesis

Chortis Vasileios , Taylor Angela , Doig Craig , Meimaridou Eirini , Metherell Lou , Arlt Wiebke , Foster Paul

Nicotinamide nucleotide transhydrogenase (NNT) is a NADPH-generating mitochondrial proton pump with a central role in mitochondrial antioxidant pathways. Recent studies revealed inactivating NNT mutations in patients with familial glucocorticoid deficiency, indicating a selective susceptibility of the adrenal cortex to NNT deficiency and oxidative stress. Here we explored the potential value of NNT as a therapeutic target in adrenocortical cancer. We delineated the distinct ef...

ea0037gp.30.07 | Endocrine tumours and neoplasia – General | ECE2015

Steroid metabolome analysis reveals that prostate cancer has potent 5α-reductase, 3α- and 17β-hydroxysteroid dehydrogenase activities, but lacks 17-hydroxylase/17,20-lyase

Hofland Johannes , Taylor Angela E , Turgeman Orli , O'Neil Donna M , Foster Paul A , Arlt Wiebke

Introduction: Prostate cancer (PC) is dependent on androgen receptor (AR) activation by its canonical ligands testosterone and 5α-dihydrotestosterone (DHT). Intratumoural androgens persisting after castration give rise to castration-resistant PC (CRPC). These intraprostatic androgen levels are hypothesized to result from either adrenal androgen conversion or intratumoural de novo DHT synthesis through the classic or alternative pathways. Quantifying the steroid f...

ea0037ep1126 | Endocrine tumours | ECE2015

Oestrogen metabolism by steroid sulphatase and 17β-hydroxysteroid dehydrogenases promotes colorectal cancer proliferation via the G-protein coupled oestrogen receptor

Gilligan Lorna , Rahman Habibur , Hewitt Anne-Marie , Taylor Angela , Morton Dion , Foster Paul

Colorectal cancer (CRC) is the third most common cancer worldwide with incidence expected to rise. Although not traditionally viewed as a hormonal cancer, evidence suggests peripheral synthesis of active oestrogens worsens prognosis. Oestrogen metabolising enzymes include steroid sulphatase (STS), which desulphates oestrogens into their active forms, and 17β-hydroxysteroid dehydrogenases (17βHSD), which are estrogen oxidoreductase enzymes. We have previously shown ST...